(Q35823410)

10 August 2017

1 reference

title

Management of chronic hepatitis C virus infection: a new era of disease control (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

1 reference

Teoh NC

1

1 reference

10 August 2017

Farrell GC

series ordinal

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Internal Medicine Journal

10 August 2017

published in

1 reference

10 August 2017

volume

34

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

324-337

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

10 August 2017

1 reference

The impact of diagnosis of hepatitis C virus on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Psychiatric disorders among veterans with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Which patients with hepatitis C develop liver complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

"Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatitis C virus infection and incident type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Association of diabetes mellitus and chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Autoimmunity and extrahepatic manifestations in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Extrahepatic manifestations of hepatitis C among United States male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

The challenge of developing a vaccine against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Severity and correlates of liver disease in hepatitis C virus-infected injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Role of alcohol in the progression of liver disease caused by hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Contribution of obesity to hepatitis C-related fibrosis progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Progression of fibrosis in untreated patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Pathologist's perspective on liver needle biopsy size?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Diagnosing fibrosis in hepatitis C: Is the pendulum swinging from biopsy to blood tests?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Optimal therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

The role of ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Adverse effects and other safety aspects of the hepatitis C antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Magnetic resonance imaging (MRI) and diseases of the liver and biliary tract. Part 1. Basic principles, MRI in the assessment of diffuse and focal hepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

Emerging therapies of hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2004.00615.X

10.1111/J.1445-5994.2004.00615.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference